[{"id":"93901ec6-cb53-4006-986c-b326980ea647","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501770","created_at":"2021-01-18T21:33:47.632Z","updated_at":"2024-07-02T16:36:26.942Z","phase":"Phase 1","brief_title":"A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors","source_id_and_acronym":"NCT04501770","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" CEACAM5 • MUC16 • CA 19-9","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • CEACAM5 expression • MUC16 expression","tags":["CEACAM5 • MUC16 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • CEACAM5 expression • MUC16 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M802"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/28/2021","start_date":" 08/28/2021","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2021-08-04"}]